Supplements
curcumin decreases liver fat in NAFLD
In plain terms: Does turmeric help fatty liver disease?
Part of: 🧪 turmeric & curcumin
Somewhat. In non-alcoholic fatty liver disease curcumin modestly lowers liver enzymes and fat, but the trials are short and heterogeneous — a promising add-on, not established therapy. (Ironically, high-dose supplements can also harm the liver — see safety.)
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Curcumin supplementation modestly reduces liver fat and lowers elevated liver enzymes (ALT/AST) in non-alcoholic fatty liver disease across several meta-analyses — but the trials are heterogeneous, short, and use varied (often phytosomal) formulations, so it's a promising adjunct rather than an established therapy.
The evidence (14)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Hui H, Guzailiayi A, Sirui H, Danping L, Abudukelimu A, Pengbo W 2026 · Biochemical and biophysical research communications | animal | supports | moderate | HFD Sprague-Dawley rats given oral curcumin for 8 weeks showed significant decreases in liver mass/index, improved liver injury markers, and reduced pro-inflammatory cytokines, with improved gut barrier and microbiota. |
| Lukkunaprasit T, Tansawet A, Boonmanunt S, Sobhonslidsuk A, McKay GJ, Attia J, Thakkinstian A 2023 · Sci Rep | meta-analysis | supports | moderate | Updated meta-analysis: curcumin improved MAFLD outcomes (hepatic steatosis and enzymes). |
| Yang K, Chen J, Zhang T, Yuan X, Ge A, Wang S, Xu H, Zeng L, Ge J 2022 · Front Immunol | meta-analysis | mixed | moderate | Meta-analysis of dietary polyphenols in NAFLD: effective evidence is limited and heterogeneous. |
| Goodarzi R, Sabzian K, Shishehbor F, Mansoori A 2019 · Phytother Res | meta-analysis | supports | moderate | Meta-analysis: turmeric/curcumin reduced serum ALT and AST in NAFLD patients. |
| Aragón-Vela J, Sánchez-Oliver AJ, Huertas JR, Casuso RA 2024 · Phytother Res | meta-analysis | mixed | moderate | Meta-analysis: substantial heterogeneity in curcumin's effect on liver aminotransferases in NAFLD. |
| Niu Y, Liu P, Chen Y, Yao Y, Bu S 2025 · Frontiers in immunology | animal | supports | moderate | HFD-induced NAFLD mice study comparing probiotic PA53 vs. curcumin as reference anti-NAFLD agent; curcumin reduced liver lipid accumulation and inflammatory cytokines but was outperformed by PA53 on weight gain and liver lipid accumulation. |
| Liu N, Li H 2024 · Medicine (Baltimore) | meta-analysis | mixed | low | Meta-analysis: phytosomal curcumin improved anthropometric/metabolic indices in NAFLD. |
| Chen M, Yao J, Liu Z 2025 · Biochemical and biophysical research communications | in-vitro | supports | low | High-glucose-induced HepG2 cell model: curcumin significantly reduced lipid accumulation (Oil Red O staining) via AMPK activation and mTOR suppression; AMPK inhibitor abolished the protective effect. |
| Konaktchieva M, Stojchevski R, Hadzi-Petrushev N, Gagov H, Konakchieva R, Mitrokhin V, Kungulovski G, Mladenov M, Avtanski D 2025 · Pharmaceuticals (Basel, Switzerland) | observational | supports | low | Narrative review on curcumin/tetrahydrocurcumin in the adipose-gut-liver axis states pilot and randomized clinical trials suggest curcumin supplementation reduces liver fat content and improves glucose/lipid metabolism, though results are h |
| Sun D, Wang J, Li X, Peng J, Wang S 2026 · Antioxidants (Basel, Switzerland) | observational | supports | low | Narrative review of curcumin's systemic metabolic effects states clinical trials corroborate that curcumin supplementation reduces liver fat content and improves liver-related markers in NAFLD patients alongside glycemic/lipid benefits. |
| Konstantinou EK, Panagiotopoulos AA, Dimitriou M 2025 · Current issues in molecular biology | mechanism | supports | low | In silico docking study found curcumin (among caffeic acid and chlorogenic acid) binds THRA with affinity comparable to T3, computationally predicted to promote fatty-acid oxidation and reduce hepatic lipid accumulation. |
| Khalili L, Nammi S 2022 · Curr Pharm Des | meta-analysis | mixed | low | Meta-analysis: curcumin improved metabolic biomarkers and BMI in liver-disease patients. |
| Gerami H, Mozaffari-Khosravi H, Mansour A, Sohrabpour AA, Poustchi H, Hashemi Taheri AP, Jaafari MR, Jambarsang S, Khayyatzadeh SS 2025 · Scientific reports | RCT | contradicts | moderate | 16-week double-blind RCT, n=55 NAFLD-fibrosis adults, 80mg/day nano-curcumin: ALT/AST/GGT/LDH significantly decreased vs placebo, but no significant between-group difference in liver fibrosis or steatosis (FibroScan/FIB-4). |
| Fan Y, Yang C, Pan J, Ye W, Zhang J, Zeng R, Chen Z, Liu X 2025 · International journal of biological macromolecules | animal | supports | moderate | HFD C57BL/6 mice given curcumin gavage for 4 weeks (after 8-week HFD induction) showed significantly attenuated hepatic lipid deposition, mediated via FTO inhibition and PPARα/CPT1α pathway activation; confirmed in HepG2/THLE-2 FFA-induced |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.